Cơ Chế Tác Dụng :
ETI-204, an affinity-enhanced monoclonal antibody (Mab), is being developed as a drug for prevention and treatment of infection and death caused by anthrax toxin.
ETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death.
Chỉ Định :
Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.